Abstract P2-11-29: IMPACT OF GERMLINE MUTATIONS ON pCR IN TRIPLE NEGATIVE BREAST CANCER PATIENTS TREATED WITH PEMBROLIZUMAB PLUS CHEMOTHERAPY: THE TIGER STUDY
Andrea Botticelli(Sapienza University of Rome), Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Pantano(Università Campus Bio-Medico), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Mazzuca(Sapienza University of Rome), Agnese Fabbri(Ospedale di Belcolle), Simona Pisegna(Sapienza University of Rome), Simone Scagnoli(Sapienza University of Rome), Francesca Sofia Di Lisa, Marianna Giampaglia(Ospedale San Carlo), Giuliana D’Auria(Ospedale di Belcolle), Paolo Sciattella(University of Rome Tor Vergata), Ilaria Portarena, Matteo Vergati(National Institutes of Health), Chiara Gullotta, Francesca Salvatori, Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Denise Drittone, Giorgia Arcuri(Università Cattolica del Sacro Cuore), Daniele Alesini, Armando Orlandi(Agostino Gemelli University Polyclinic)
Cited by 0
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|327
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
|Cancer Immunology Immunotherapy|2009|298